Human Peripheral Blood B Cells, Frozen

Primary human cells, frozen

More Views

From: 880 USD

Options

* Required Fields

Catalog # (Select a product)
Primary human cells, frozen
From: 880 USD

Overview

Human primary B cells derived from peripheral blood (PB) are isolated from mononuclear cells (MNCs) using the negative immunomagnetic selection technique. Cells are untouched and ready for downstream applications. PB was collected using one of the following anticoagulants: acid-citrate-dextrose (ACD), acid-citrate-dextrose solution A (ACDA), citrate-phosphate-dextrose (CPD), citrate-phosphate-double-dextrose (CP2D), or citrate-phosphate-dextrose-adenine (CPDA).

Cells were obtained using Institutional Review Board (IRB)-approved consent forms and protocols.

Certain products are only available in select territories. Please contact your local Sales representative or Product & Scientific Support at techsupport@stemcell.com for further information.
Contains:
• CryoStor® CS10
Subtype:
Frozen
Cell Type:
B Cells
Species:
Human
Cell and Tissue Source:
Peripheral Blood
Donor Status:
Normal
Purity:
The purity of B cells is ≥ 85% by flow cytometry.

Scientific Resources

Product Documentation

Document Type
Product Name
Catalog #
Lot #
Language

Educational Materials

(2)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Data

Figure 1. Cryopreserved B Cells Show High Viability and Produce IgG Antibodies Upon Stimulation

(A) B Cells (Catalog #70023) cryopreserved in CryoStor® CS10 (Catalog #07930) show high viability upon thawing (average = 96.3 ± 0.6 %, n = 6). (B) B cells were cultured for 1 week in RPMI 1640 Medium (Catalog #36750) with 10% FBS, 2mM L-Glutamine (Catalog #07100), 10mM HEPES (Catalog #07200) and 55 µM β-mercaptoethanol and either left unstimulated (control) or stimulated with CD40 in the presence of IL-21 (activated). Activated B cells produce significantly more IgG antibodies compared to unstimulated controls as measured by ELISA.

Publications

(1)
Journal of medicinal chemistry 2014 MAY

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.

Currie KS et al.

Abstract

Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncology disease indications. The most advanced Syk inhibitor, R406, 1 (or its prodrug form fostamatinib, 2), has shown efficacy in multiple therapeutic indications, but its clinical progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of 1. It is expected that a more selective Syk inhibitor would provide a greater therapeutic window. Herein we report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors. This work culminated in the identification of GS-9973, 68, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications.
STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.